Prolintane

Prolintane (Catovit, Katovit, Promotil, Villescon) is a stimulant[2] and norepinephrine-dopamine reuptake inhibitor developed in the 1950s.[3] Being an amphetamine derivative, it is closely related in chemical structure to other drugs such as pyrovalerone, MDPV, and propylhexedrine and it has a similar mechanism of action.[4] Many cases of prolintane abuse have been reported.[5]

Prolintane
Clinical data
Routes of
administration		oral, intranasal, rectal
ATC code
Legal status
Legal status
  • AU: S4 (Prescription only)
  • BR: Class B1 (Psychoactive drugs)[1]
Identifiers
  • 1-(1-phenylpentan-2-yl)pyrrolidine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
ECHA InfoCard100.007.077
Chemical and physical data
FormulaC15H23N
Molar mass217.356 g·mol−1
3D model (JSmol)
Melting point133 °C (271 °F)
Boiling point153 °C (307 °F)
  • CCCC(N1CCCC1)CC2=CC=CC=C2
  • InChI=1S/C15H23N/c1-2-8-15(16-11-6-7-12-16)13-14-9-4-3-5-10-14/h3-5,9-10,15H,2,6-8,11-13H2,1H3 checkY
  • Key:OJCPSBCUMRIPFL-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Under the trade-name "Katovit", prolintane was commercialized by the Spanish pharmaceutical company, FHER. Katovit was sold until 2001, and was most often used by students and workers as a stimulant to provide energy, promote alertness and concentration.

See also

References
  1. Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
  2. Hollister LE, Gillespie HK (March–April 1970). "A new stimulant, prolintane hydrochloride, compared with dextroamphetamine in fatigued volunteers". The Journal of Clinical Pharmacology and the Journal of New Drugs. 10 (2): 103–9. doi:10.1177/009127007001000205. PMID 4392006.
  3. GB Patent 807835
  4. Nicholson AN, Stone BM, Jones MM (November 1980). "Wakefullness and reduced rapid eye movement sleep: studies with prolintane and pemoline". British Journal of Clinical Pharmacology. 10 (5): 465–72. doi:10.1111/j.1365-2125.1980.tb01790.x. PMC 1430138. PMID 7437258.
  5. Kyle PB, Daley WP (September 2007). "Domestic abuse of the European rave drug prolintane". Journal of Analytical Toxicology. 31 (7): 415–8. doi:10.1093/jat/31.7.415. PMID 17725890.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.